Inflection to present breast cancer drug data
Irish drug development company Inflection Biosciences will present data on its fledgling breakthrough breast cancer therapy to the American Association for Cancer Research annual meeting on Monday.
The Dublin company is working on a drug that it believes will give hope to women with treatment-resistant breast cancer.
Its IBL-302 molecule aims to shut down two separate pathways commonly used by cancer cells to spread. Much current therapy is focused on shutting down, or inhibiting, what is called the PI3K pathway.
The trouble is that when this pathway is blocked by cancer drugs, the cancer cells find other pathways to continue the spread of the disease. Researchers at the Dana Farber Cancer Institute in Boston suggested that targeting the PI3K pathway and a separate gene, PIM2, together could deliver therapeutic benefits, halting the spread of cancer for a while.
Inflection’s IBL-302 molecule is the only therapy currently targeting both these cancer pathways.
Inflection chief executive Darren Cunningham and his co-founder Dr Michael O’Neill found the drug in a pipeline of molecules that they licensed from the Spanish National Cancer Research Centre in 2013, having previously looked at the potential of up to 150 other options.
“It has taken us 3½ years, including fund-raising, to get to this point,” says Mr Cunningham. The next stage is getting the drug into patients in a phase I trial to test both safety and efficacy.
Excited about prospects
Prof Bryan Hennessy, a consultant oncologist and senior lecturer at the Royal College of Surgeons, who has worked on getting IBL-302 to this point, is excited about its prospects.
“Nobody else is looking at a drug like this,” he says. “We have been through a lot of preclinical work and it is quite advanced.”
Funding a phase I trial will cost in the region of €10 million and Mr Cunningham, whose background is in business development at Elan, is confident of getting to that point within 18 months.
Inflection already has support from Enterprise Ireland and life science-focused venture capital group Fountain Healthcare. Michael Smurfit is another investor.